NBTX
NanobiotixNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.80B
P/E Ratio
—
EPS
$-0.58
Beta
0.59
52W High
$57.14
52W Low
$4.18
50-Day MA
$37.51
200-Day MA
$25.94
Dividend Yield
—
Profit Margin
-73.50%
Forward P/E
95.24
PEG Ratio
—
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
Fundamentals
| Revenue (TTM) | $32.59M |
| Gross Profit (TTM) | $32.59M |
| EBITDA | $-10.49M |
| Operating Margin | -196.40% |
| Return on Equity | -198.70% |
| Return on Assets | -10.10% |
| Revenue/Share (TTM) | $0.68 |
| Book Value | $-2.01 |
| Price-to-Book | 65.02 |
| Price-to-Sales (TTM) | 55.38 |
| EV/Revenue | 51.12 |
| EV/EBITDA | -2.45 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 186.80% |
| Shares Outstanding | $50.79M |
| Float | $31.82M |
| % Insiders | 0.00% |
| % Institutions | 11.76% |
Historical Volatility
HV 10-Day
63.18%
HV 20-Day
60.24%
HV 30-Day
113.77%
HV 60-Day
95.47%
HV Rank
73.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($42.75 target)
5
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026